Healthcare
Immunicom
View On Demand
A hybrid cancer therapy which combines the best of a medical device with targeted drug therapy.
Menu
A hybrid cancer therapy which combines the best of a medical device with targeted drug therapy.
Inmedix has adapted the next generation of Heart Rate Variability testing as a diagnostic aid across a variety of conditions
Learn more about Aruna’s innovative new drug platform and how it can be used to delivery a wide variety of therapeutics to the brain.
Pressure BioScience CEO, Richard Schumacher discusses their patented Ultra Shear Technology and the potential it has to transform plant-based products.
5 million COPD patients experiencing airway blockages can be treated with Aer-01 from Aer Therapeutics
The diagnostic market for stress-related diseases is $60B. Inmedix has developed a way to measure stress with two recurrent revenue streams and 90% SaaS margins.
Immunicom has developed a hybrid cancer therapy which combines the best of a medical device with targeted drug therapy
Dr. John Abeles and Bryologyx CEO, Thomas Loarie, share their best practices in healthcare investing.
Learn more about Preverna’s revolutionary approach to cancer drug development and how they’re working with others to improve cancer care.
Invectys President and CEO, Praveen Tyle, discuses the company’s three platforms and the technology that has the potential to cure metastatic cancers
1460 Broadway
New York, NY 10036
(917) 747-6198
© Copyright 2021 FORCE Family Office